top of page

Research Roundup: Sept 20, 2021

Best of the Week...

Zynerba presents their new Phase 2 data on their transdermal CBD gel for treating autism

Longer Term Tolerability and Efficacy of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Autism Spectrum Disorder (ASD): An Open-Label Phase 2 Study

This review takes a deep dive into the data on CBD for Alzheimer’s disease

Understanding the Modulatory Effects of Cannabidiol on Alzheimer’s Disease

A review of the effects of cannabis & the cannabinoids like CBD on athletic performance

Cannabis and Athletic Performance

In humans, younger people have more CB1 receptors in their muscle than older people – but you can increase your cannabinoid receptor levels with resistance exercise

Cannabinoid receptor 1 expression is higher in muscle of old vs. young males, and increases upon resistance exercise in older adults

A review of the use of cannabinoids for skin health

Topical Use of Cannabis sativa L. Biochemicals

American Family Physician reviews the positive evidence on melatonin for sleep

Melatonin to Treat Insomnia in Older Adults

Dr. Piomelli reviews the promise of endocannabinoid-based therapies

Endocannabinoid-Based Therapies

Clinical Studies & Reviews of CBD & the Endocannabinoid System (ECS)

A review of the use of cannabinoids in dentistry with a special focus on CBD

The Current and Potential Application of Medicinal Cannabis Products in Dentistry

A case report of a man with ALS & severe itching who used oral cannabinoids to treat his skin condition

Cannabinoids for the treatment of refractory neuropathic pruritus in amyotrophic lateral sclerosis: A case report

In humans with COVID-19, a certain genetic variant of the CB2 receptor leads to worse outcomes

Functional variation (Q63R) in the cannabinoid CB2 receptor may affect the severity of COVID-19: a human study and molecular docking

A review of the other receptors that may one day be known as endocannabinoid receptors (hattip to Stuart Tomc)

Endocannabinoid signaling pathways: beyond CB1R and CB2R

A review of using the cannabinoids to treat the pain of MS

Efficacy, tolerability and safety of cannabinoids for management of pain in adult patients with multiple sclerosis: A systematic review and meta-analysis

Preclinical Research & Cannabinoid Chemistry

The CB2 receptor is a key pathway to control homeostasis of our brain’s microglia (immune cells that respond to potential threats) Cannabinoid receptor 2 is necessary to induce toll-like receptor-mediated microglial activation In a mouse model of inflammatory pain, treatment with JNK (a novel pain inhibitor) works via the CB2 receptor in females & by both the CB1 & CB2 receptor in males Sex and dose-dependent antinociceptive effects of the JNK (c-Jun N-terminal kinase) inhibitor SU 3327 are mediated by CB2 receptors in female, and CB1/CB2 receptors in male mice in an inflammatory pain model In mice with no CB1 receptors in their liver cells, they saw no difference in their response to a high fat diet & concluded that the CB1 receptors had no direct role in the development of nonalcoholic fatty liver disease or liver fibrosis Cannabinoid receptor-1 signaling in hepatocytes and stellate cells does not contribute to NAFLD In a fruit fly model of depression, an extract made from hemp seeds alleviated depression symptoms & modulated the circadian rhythm (hattip to Stuart Tomc, who somehow found this 3 months before it’s publication date)

Anti-depressant effects of ethanol extract from Cannabis sativa (hemp) seed in chlorpromazine-induced Drosophila melanogaster depression model


bottom of page